Apogee Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Apogee Therapeutics generated cash of -$74,761,000, which is less than the previous year. Cash used in financing activities reached the amount of $315,391,000 last year. Net change in cash is therefore -$33,280,000.
Cash Flow
| 2022 | -16.42M | 0 | 183.61K |
|---|---|---|---|
| 2023 | -74.76M | -273.91M | 315.39M |
APGE Cash Flow Statement (2022 – 2023)
| 2023 | 2022 | |
|---|---|---|
Cash at beginning of period | 151.89M | 168.13M |
Operating activities | ||
Net income | -83.98M | -39.78M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||
Depreciation and amortization | 0 | 0 |
Stock-based compensation expense | 6.10M | 2.14M |
| Deferred income tax benefit | 6.10M | 2.14M |
| Changes in operating assets and liabilities: | ||
Accounts receivable, net | 0 | 0 |
Inventories | 0 | 0 |
Accounts payable | 1.61M | 418K |
Cash generated by operating activities | -74.76M | -16.42M |
Investing activities | ||
Purchases Of Investments | -303.74M | 0 |
Investments In Property Plant And Equipment | -167K | 0 |
Acquisitions Net | 0 | 0 |
Cash generated by investing activities | -273.91M | 0 |
Financing activities | ||
Common Stock Issued | 315.39M | 168.31M |
Payments for dividends | 0 | 0 |
Repurchases of common stock | 0 | 0 |
Repayments of term debt | 0 | 0 |
Cash used in financing activities | 315.39M | 183.61K |
Net Change In Cash | -33.28M | -16.24M |
Cash at end of period | 118.61M | 151.89M |
| Data source |